Loading stock…

Chemed Corporation (CHE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Chemed Corporation

CHEMarket cap $6.48BPrice $498.3

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Runs VITAS Healthcare, the largest hospice provider in America, alongside Roto-Rooter's plumbing and drain services. Yes, one company profits from both end-of-life care and clogged toilets — an odd pairing that's quietly delivered decades of consistent growth.

In Bastion Portfolios?

52W Return+13%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+8%5

Rev CAGR (3y)+7%5

Rev CAGR (5y)+5%5

Earnings Forecast

EPS Growth Y+1+42%9

EPS Growth Y+2+6%6

EPS Growth Y+3+6%5

Quality

Margins

EBIT Margin14%6

Net Income Margin11%6

Free Cash Flow Margin12%6

Debt

Net Debt/EBITDA0.57

Efficiency

ROE27%9

ROA17%10

Earnings Stability55

GEAR+STRONG79

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)194

P/E Ratio (Forward 3y)174

P/BV7.82

EV Multiples

EV/EBITDA Fwd134

EV/EBIT Fwd156

Yield

Free Cash Flow Yield5.0%6

Dividend Yield0.6%2

Momentum

Short term

1 month return-4%5

3 month return+2%7

YTD return+17%7

Mid term

Price vs 52wHigh90%8

1 year return+16%7

Long term

3 year return-2%3

5 year return+22%5

Risk Shield

Price Risk

Beta0.39

Volatility30%7

Free Cash Flow

Free Cash Flow Margin12%6

Free Cash Flow Yield5.0%6

Quality

ROCE26%9

Earnings Stability55

Net Debt/EBITDA0.57

02Growth

Is it actually growing, and how fast?

CHEChemed

Revenue FY25$2.5B

GROWTH RATING↗

AVERAGE47 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+42%9

EPS growth, FY27E+6%6

EPS growth, FY28E+6%5

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 6%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 47% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE57 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+2%7

YTD return+17%7

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+16%7

3-year return-2%3

5-year return+22%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 16% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+2%) and so far this year (+17%).

WATCH

Average long-term results. Multi-year returns are middling (-2.4% over three years and +22% over five), roughly average for the market.

Returns sit at the market level over the past month (-4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Chemed. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CHEChemed

Revenue FY25$2.5B

GROWTH RATING↗

AVERAGE47 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+8%5

Revenue, next 3Y, CAGR+7%5

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+42%9

EPS growth, FY27E+6%6

EPS growth, FY28E+6%5

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 6%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 47% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE57 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%5

3-month return+2%7

YTD return+17%7

MID & LONG-TERM▾SCORE

% of 52-week high90%8

1-year return+16%7

3-year return-2%3

5-year return+22%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 16% over the past year, but 10% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over three months (+2%) and so far this year (+17%).

WATCH

Average long-term results. Multi-year returns are middling (-2.4% over three years and +22% over five), roughly average for the market.

Returns sit at the market level over the past month (-4%).

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Chemed. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community